HOW CHIMPANZEES PROCESS & OVERCOME SOCIALLY NEGATIVE EVENTS

该项目评估了两种剂量的4种不同的 生长激素受体拮抗剂的制剂， 正在接受肢端肥大症的治疗 疗效 由药物抑制血清浓度的能力决定 胰岛素样生长因子（IGF）-I和IGF结合蛋白（IGFBP） -3. 这项研究的结果提供了重要的新信息 成功的治疗肢端肥大症 在 此外，这些研究还为开发 GH受体缺乏的动物模型，可用于研究 增长和发展。 资助Sensus Drug Development Corp. 35，200美元 1998年1月7日至1999年6月30日出版物无P51 RR 00165 -38 1998年1月1日至1998年12月31日 耶基斯地区灵长类动物研究中心

This project evaluated the efficacy of two doses of 4 different formulations of a growth hormone receptor antagonist currently under being examined for the treatment of acromegaly. Efficacy was determined by the ability of the drug to suppress serum concentrations of insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP) -3. The results of this study provided significant new information for the advancing a successful treatment regimen in acromegalics. In addition, these studies provide new information for the development of an animal model of GH receptor deficiency that could be used to study growth and development. FUNDING Sensus Drug Development Corp. $35,200 07/01/98 - 6/30/99 PUBLICATIONS None P51RR00165-38 1/1/98 - 12/31/98 Yerkes Regional Primate Research Center